Schizophrenic Symptoms Improve with Apomorphine
- 5 May 1978
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 200 (4341) , 567-568
- https://doi.org/10.1126/science.347574
Abstract
Eighteen chronic schizophrenic patients received subcutaneous doses of apomorphine, a dopamine receptor agonist, and of placebo in separate trials. A significant improvement in psychotic symptoms occurred after apomorphine compared to placebo. The results are interpreted as a consequence of presynaptic dopamine receptor activation by apomorphine with a subsequent decrease in dopamine-mediated neural transmission.This publication has 14 references indexed in Scilit:
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976
- Potentiation by Metyrosine of Thioridazine Effects in Chronic SchizophrenicsArchives of General Psychiatry, 1976
- Huntington's DiseaseAnnual Review of Medicine, 1975
- Apomorphine in huntington's chorea: Clinical observations and theoretical considerationsLife Sciences, 1974
- Drugs, Neurotransmitters, and SchizophreniaScience, 1974
- A Checklist for the Diagnosis of SchizophreniaThe British Journal of Psychiatry, 1972
- Catecholamines in the Brain as Mediators of Amphetamine PsychosisArchives of General Psychiatry, 1972
- Mode of action of apomorphine and dexamphetamine on gnawing compulsion in ratsPsychopharmacology, 1967
- Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse BrainActa Pharmacologica et Toxicologica, 1963
- A NOTE ON APOMORPHINE AS A SEDATIVEAmerican Journal of Psychiatry, 1945